Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Summit Therapeutics buys Discuva for cash and stock

Executive Summary

Expanding its infectious disease pipeline, Summit Therapeutics PLC acquired private fellow UK-based firm Discuva Ltd. for £5mm ($6.68mm) in cash and £5mm in stock (2.93mm new ordinary shares at £1.70 each, a 2.7% premium).
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Intra-Biotech Deal
    • Full Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register